Fig. 6

Effects of enzalutamide treatment are recapitulated in responsive and non-responsive prostate cancer xenografts. A Immunohistochemistry displaying Ki67 and GL13 stainings in serial sections of LNCaP mouse xenografts receiving enzalutamide (10 mg/kg) or no treatment (Control). Enzalutamide-treated xenografts display reduced proliferation and increased senescence compared to control. B Quantification of Ki67 and GL13 stainings in A. C Western blotting of cell lysates from LNCaP xenografts in A, using the indicated markers. Densitometry was carried out for all markers. See also Fig. S8A. D q-PCR for GATA2 levels in cell lysates from LNCaP xenografts in A. E Immunohistochemistry displaying Ki67 and GL13 stainings in serial sections of C4-2B mouse xenografts receiving enzalutamide (10 mg/kg) or no treatment (Control). F Quantification of Ki67 and GL13 stainings in E. G Western blotting of cell lysates from C4-2B xenografts in E, using the indicated markers. Densitometry was carried out for all markers. See also Fig. S8B. H q-PCR for GATA2 levels in cell lysates from C4-2B xenografts in E. Magnification: 200x (Objective 20x), scale bars: 30 μm. Inset magnification: 400x (Objective 40x). *P < 0.05 and ***P < 0.001, of Student’s t-test; n.s., non-significant. Error bars indicate s.e.m. Data shown are representative of at least 3 biological experiments (n ≥ 3)